Skip to content
DataLookout
Menu

WINDWARDNCT06475781

Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Sep 22, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 11 → 15 locations
  2. Notable Eligibility criteria expanded, about 49 words
    • Study sites: 9 to 11
    • Secondary endpoints: details revised at 2 of 6 entries
  3. Notable Eligibility criteria expanded, about 135 words
    • Study description shortened, about 16 words
    v13
  4. Minor Primary and study completion dates moved earlier to Feb 2028
    • Site details revised at 7 of 9 sites
    • Collaborator revised
    • Study title expanded, about 1 word
    v12
  5. Notable Eligibility criteria expanded, about 2 wordsv11
Show 9 earlier versionsHide 9 earlier versions
  1. Minor Site details revised at 7 of 9 sitesv10
  2. Minor Study sites: 8 to 9v9
  3. Minor Site details revised at 1 of 8 sitesv8
  4. Minor Study sites: 7 to 8v7
  5. Minor Study sites: 6 to 7v6
  6. Minor Study sites: 4 to 6v5
  7. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2025 to Mar 1, 2025
    • Site details revised at 4 of 4 sites
    v4
  8. Notable Start date: Dec 2024 to Apr 2025
    • Study sites: 0 to 4
    v3
  9. Minor Secondary endpoints: details revised at 3 of 6 entriesv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Pulmonary Vascular Resistance (PVR)
Timeframe: 12 weeks

Secondary (6)

6-minute walk distance
Time to clinical deterioration from baseline to Week 12 for any of the following ADJUDICATED clinical events
Long-term prognostic risk factors
Patient-reported outcome measures (PROMS): (SF)-36v2
Patient-reported outcome measures (PROMS): WIQ
Show 1 moreShow less
Patient-reported outcome measures (PROMS): PAH-SYMPACT

Arms and interventions

150 mg mirivadelgatExperimental

150 mg mirivadelgat once daily

300 mg mirivadelgatExperimental

300 mg mirivadelgat once daily

placeboPlacebo comparator

placebo once daily

Drugs: Mirivadelgat, placebo

Sites

15 sites in 3 countries

Taiwan 9, Georgia 4, Bosnia and Herzegovina 2